We advised the joint lead managers and joint bookrunners on the offering

Davis Polk advised the joint lead managers and joint bookrunners in connection with the primary offering of 51,304,400 shares of common stock of Sumitomo Pharma Co., Ltd. The shares are listed on the Tokyo Stock Exchange and were offered outside Japan pursuant to Rule 144A and Regulation S. The aggregate proceeds of the offering are approximately ¥102.1 billion (approximately $639 million).

Sumitomo Pharma is an R&D-driven pharmaceutical company headquartered in Japan, with significant operations in North America. It discovers, develops, manufactures and commercializes prescription pharmaceuticals, including drugs and biologics such as regenerative medicine and cell therapy programs.

The Davis Polk corporate team included partner Christopher Kodama, counsel Chihiro Sasaki and associate Akiko Okamoto. Partner David R. Bauer and associate Nazli Ungan provided intellectual property advice. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Ya Sheng Lin provided tax advice. Counsel Chaoyuan (Charles) Shi provided ERISA advice. Members of the Davis Polk team are based in the Tokyo, New York and London offices.

Copy link to share post